Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
82,815,631
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
22,128,108
-
Shares change
-
+1,389,049
-
Total reported value, excl. options
-
$230,547,815
-
Value change
-
+$14,765,407
-
Put/Call ratio
-
23.82%
-
Number of buys
-
29
-
Number of sells
-
-26
-
Price
-
$10.42
Significant Holders of EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT) as of Q3 2021
77 filings reported holding EYPT - EyePoint Pharmaceuticals, Inc. - Common Stock as of Q3 2021.
EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22,128,108 shares
of 82,815,631 outstanding shares and own 26.72% of the company stock.
Largest 10 shareholders include Essex Woodlands Management, Inc. (4,190,921 shares), FRANKLIN RESOURCES INC (3,174,337 shares), RA CAPITAL MANAGEMENT, L.P. (2,210,506 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1,763,031 shares), SUVRETTA CAPITAL MANAGEMENT, LLC (1,704,589 shares), BlackRock Inc. (1,190,633 shares), VANGUARD GROUP INC (1,092,306 shares), CITADEL ADVISORS LLC (946,424 shares), DRIEHAUS CAPITAL MANAGEMENT LLC (751,441 shares), and JANUS HENDERSON GROUP PLC (712,384 shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.